Cargando…

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study

OBJECTIVE: Due to a high efficacy in clinical trials, sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and effectiveness of these regimens for GT2 in HCV-TARGET participants. DESIGN: HCV-TARGET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Welzel, Tania M, Nelson, David R, Morelli, Giuseppe, Di Bisceglie, Adrian, Reddy, Rajender K, Kuo, Alexander, Lim, Joseph K, Darling, Jama, Pockros, Paul, Galati, Joseph S, Frazier, Lynn M, Alqahtani, Saleh, Sulkowski, Mark S, Vainorius, Monika, Akushevich, Lucy, Fried, Michael W, Zeuzem, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595101/ https://www.ncbi.nlm.nih.gov/pubmed/27418632 http://dx.doi.org/10.1136/gutjnl-2016-311609

Ejemplares similares

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
por: Shiha, Gamal, et al.
Publicado: (2019)

Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis
por: Radhakrishnan, Kavita, et al.
Publicado: (2019)

Economic study of the value of expanding HCV treatment capacity in Germany
por: Sbarigia, Urbano, et al.
Publicado: (2017)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Host cell mTORC1 is required for HCV RNA replication
por: Stöhr, Stefanie, et al.
Publicado: (2016)

Defining the key intrahepatic gene networks in HCV infection driven by sex
por: Marchi, Emanuele, et al.
Publicado: (2023)

Remaining challenges in HCV elimination
por: Capraru, Camelia, et al.
Publicado: (2021)

Hyperbilirubinaemia in HIV–HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?
por: Kaspar, Matthew B, et al.
Publicado: (2016)

An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin
por: Poordad, Fred, et al.
Publicado: (2017)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients
por: Smirne, Carlo, et al.
Publicado: (2022)

Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis
por: Nguyen, Nghia H, et al.
Publicado: (2016)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis
por: Tucci, Francesca, et al.
Publicado: (2018)

Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection
por: Fitzmaurice, Karen, et al.
Publicado: (2015)

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice
por: Prentoe, Jannick, et al.
Publicado: (2016)

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
por: Orr, Cody, et al.
Publicado: (2020)

Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China
por: Chen, Liyu, et al.
Publicado: (2021)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
por: Hassuna, Noha Anwar, et al.
Publicado: (2022)

Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection
por: Keng, Choong Tat, et al.
Publicado: (2016)

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape
por: Colpitts, Che C, et al.
Publicado: (2018)

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017)

Novel host genetic variations associated with spontaneous clearance of a single-source outbreak of HCV1b infections
por: You, Hong, et al.
Publicado: (2015)

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design
por: von Delft, Annette, et al.
Publicado: (2016)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
por: Van, Nguyen Dinh, et al.
Publicado: (2016)

No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and Its Vicinity
por: Hirosawa, Takuya, et al.
Publicado: (2018)

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis
por: Van Renne, Nicolaas, et al.
Publicado: (2018)

In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
por: Todt, Daniel, et al.
Publicado: (2016)

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
por: Sacco, Rodolfo, et al.
Publicado: (2020)

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients
por: Hatu, Giorgiana, et al.
Publicado: (2014)

Sofosbuvir, a Significant Paradigm Change in HCV Treatment
por: McQuaid, Thomas, et al.
Publicado: (2015)

HCV Council – critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape
por: Reau, Nancy, et al.
Publicado: (2015)

Serum aminotransferase ratio is independently correlated with hepatosteatosis in patients with HCV: a cross-sectional observational study
por: Lin, Ming-Shyan, et al.
Publicado: (2015)

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
por: Golabi, Pegah, et al.
Publicado: (2016)

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
por: Takehara, Tetsuo, et al.
Publicado: (2018)

Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study
por: Chang, Te-Sheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hidbqp8dfsqv0cq0gj97257umh